Biomnis >> Latest News >> NEW TEST: Pre-eclampsia Prediction Screening

NEW TEST: Pre-eclampsia Prediction Screening

Sidebar Image

Pre-eclampsia is a complication that can occur during pregnancy. It is the number one cause of maternal morbi-mortality in the developed world and can be as high as 10% in high risk populations.

Pre-eclampsia screening combines the following elements: the assaying of serum PLGF (Placenta Growth Factor) and PAPP-A performed on a sample collected during the first trimester.

Information concerning the patient and the pregnancy underway (information form must be sent along with the sample.Once made aware of a risk of pre-eclampsia, the doctor can initiate a treatment. This is why screening is of clinical interest before this date.


Method: time resolved fluoroimmunoassay

Sample requirements: Plain tube. 1 tube (3mL) specifically assigned to pre-eclampsia testing. Following removal of the coagulated mass and centrifugation to separate the serum.

Storage and transport: refrigerated


1. The risk of pre-eclampsia is calculated only:

· During the first trimester of pregnancy (between 11.0 and 13.6 weeks of amenorrhea)

· For a single-foetus pregnancy

2. The arterial blood pressure should ideally be taken at both arms simultaneously. If this cannot be done, one arm is sufficient.

3. A maximum delay of 10 days between the ultrasound scan, the taking of the patient’s blood pressure and the blood sample must be respected.

For further information on this test please contact Eurofins Biomnis on (01) 295 8545 or email us at